These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37058012)

  • 1. Correlation between blood concentration of roxadustat and clinical efficacy in patients with anemia of chronic kidney disease.
    Zhang Y; Jing Y; Zhou C
    Medicine (Baltimore); 2023 Apr; 102(15):e33564. PubMed ID: 37058012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials.
    Provenzano R; Szczech L; Leong R; Saikali KG; Zhong M; Lee TT; Little DJ; Houser MT; Frison L; Houghton J; Neff TB
    Clin J Am Soc Nephrol; 2021 Aug; 16(8):1190-1200. PubMed ID: 34362786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study.
    Fishbane S; El-Shahawy MA; Pecoits-Filho R; Van BP; Houser MT; Frison L; Little DJ; Guzman NJ; Pergola PE
    J Am Soc Nephrol; 2021 Mar; 32(3):737-755. PubMed ID: 33568383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.
    Chen N; Hao C; Peng X; Lin H; Yin A; Hao L; Tao Y; Liang X; Liu Z; Xing C; Chen J; Luo L; Zuo L; Liao Y; Liu BC; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP
    N Engl J Med; 2019 Sep; 381(11):1001-1010. PubMed ID: 31340089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.
    Provenzano R; Besarab A; Sun CH; Diamond SA; Durham JH; Cangiano JL; Aiello JR; Novak JE; Lee T; Leong R; Roberts BK; Saikali KG; Hemmerich S; Szczech LA; Yu KP; Neff TB
    Clin J Am Soc Nephrol; 2016 Jun; 11(6):982-991. PubMed ID: 27094610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
    Besarab A; Provenzano R; Hertel J; Zabaneh R; Klaus SJ; Lee T; Leong R; Hemmerich S; Yu KH; Neff TB
    Nephrol Dial Transplant; 2015 Oct; 30(10):1665-73. PubMed ID: 26238121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study.
    Akizawa T; Otsuka T; Reusch M; Ueno M
    Ther Apher Dial; 2020 Apr; 24(2):115-125. PubMed ID: 31222951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of roxadustat in the treatment of renal allograft anemia patients: a case series.
    Li J; Ma K; Wang L; Qi H; Lv J; Rao Y; Peng W
    Ann Palliat Med; 2021 Nov; 10(11):11859-11867. PubMed ID: 34872310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.
    Chen N; Hao C; Liu BC; Lin H; Wang C; Xing C; Liang X; Jiang G; Liu Z; Li X; Zuo L; Luo L; Wang J; Zhao MH; Liu Z; Cai GY; Hao L; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP
    N Engl J Med; 2019 Sep; 381(11):1011-1022. PubMed ID: 31340116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of roxadustat treatment for anemia in patients with kidney disease: a meta-analysis and systematic review.
    Qie S; Jiao N; Duan K; Li J; Liu Y; Liu G
    Int Urol Nephrol; 2021 May; 53(5):985-997. PubMed ID: 33389461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Food and Spherical Carbon Adsorbent Effects on the Pharmacokinetics of Roxadustat in Healthy Nonelderly Adult Male Japanese Subjects.
    Shibata T; Nomura Y; Takada A; Ueno M; Katashima M; Yazawa R; Furihata K
    Clin Pharmacol Drug Dev; 2019 Apr; 8(3):304-313. PubMed ID: 29966038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
    Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
    J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies.
    Akizawa T; Ueno M; Shiga T; Reusch M
    Ther Apher Dial; 2020 Dec; 24(6):628-641. PubMed ID: 31891449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.
    Akizawa T; Iwasaki M; Otsuka T; Reusch M; Misumi T
    Adv Ther; 2019 Jun; 36(6):1438-1454. PubMed ID: 30953333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
    Provenzano R; Tumlin J; Zabaneh R; Chou J; Hemmerich S; Neff TB; Yu KP
    J Clin Pharmacol; 2020 Nov; 60(11):1432-1440. PubMed ID: 32603526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Renal Anemia in Patients With Hemodialysis Using Hypoxia-inducible Factor (HIF) Stabilizer, Roxadustat: A Short-term Clinical Study.
    Mima A; Horii Y
    In Vivo; 2022; 36(4):1785-1789. PubMed ID: 35738640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and economic evaluation of roxadustat treatment for anemia in patients with kidney disease not receiving dialysis.
    Hu Z; Tao H; Shi A; Pan J
    Expert Rev Pharmacoecon Outcomes Res; 2020 Aug; 20(4):411-418. PubMed ID: 32249625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study.
    Fishbane S; Pollock CA; El-Shahawy M; Escudero ET; Rastogi A; Van BP; Frison L; Houser M; Pola M; Little DJ; Guzman N; Pergola PE
    J Am Soc Nephrol; 2022 Apr; 33(4):850-866. PubMed ID: 35361724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
    Akizawa T; Iwasaki M; Yamaguchi Y; Majikawa Y; Reusch M
    J Am Soc Nephrol; 2020 Jul; 31(7):1628-1639. PubMed ID: 32493693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
    Akizawa T; Yamaguchi Y; Otsuka T; Reusch M
    Nephron; 2020; 144(8):372-382. PubMed ID: 32580188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.